ST8SIA1 and cancer: The development of new GD3S inhibitors, which could be used in combination with conventional therapies, especially those targeting complex gangliosides (anti-GD2 mAb immunotherapies) or RTKs, is a promising concept for the treatment of the most aggressive GD3/GD2 positive cancers.